Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GLAXO-WELLCOME RANITIDINE BISMUTH CITRATE PLUS CLARITHROMYCIN NDA STUDIES SHOW 82%-94% ERADICATION OF H. PYLORI; ABBOTT URGES "STRINGENT" TEST STANDARDS

Executive Summary

Eradication rates of ranitidine bismuth citrate plus clarithromycin ranged between 82%-94% in six unpublished studies, Glaxo-Wellcome Gastroenterology Director Arthur Ciociola, PhD, reported at a joint meeting of FDA's Gastrointestinal and Anti-Infective Drugs Advisory Committees Oct. 26.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS027148

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel